TAK
Takeda Pharmaceutical Company Limited NYSE$16.56
Mkt Cap $52.3B
52w Low $12.99
60.4% of range
52w High $18.90
50d MA $17.90
200d MA $15.78
P/E (TTM)
0.5x
EV/EBITDA
9.3x
P/B
0.0x
Debt/Equity
0.7x
ROE
—
P/FCF
8.4x
RSI (14)
—
ATR (14)
—
Beta
0.13
50d MA
$17.90
200d MA
$15.78
Avg Volume
2.9M
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company pro…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 29, 2026 | AMC | 0.55 | 0.48 | -12.7% | 17.17 | -0.5% | +0.3% | +1.9% | +1.5% | +3.3% | +3.7% | — |
| Oct 30, 2025 | AMC | 0.44 | 0.44 | +0.0% | 13.23 | +1.4% | +1.6% | +1.4% | +2.5% | +2.7% | +3.1% | — |
| Jul 30, 2025 | AMC | 0.47 | 0.52 | +10.6% | 13.60 | +2.1% | +0.9% | +4.1% | +4.9% | +4.4% | +4.9% | — |
| Jun 25, 2025 | AMC | — | -0.22 | — | 14.97 | +0.8% | +0.6% | +0.9% | +3.3% | +2.7% | +3.0% | — |
| Jan 30, 2025 | AMC | 0.63 | 0.42 | -33.3% | 13.70 | -1.0% | -2.3% | -3.3% | -2.8% | -2.4% | -0.7% | — |
| Oct 31, 2024 | AMC | 0.39 | 0.44 | +12.8% | 13.94 | +0.4% | +0.1% | +0.8% | +2.0% | -1.1% | -0.6% | — |
| Jul 31, 2024 | AMC | 0.37 | 0.56 | +51.4% | 13.88 | -2.0% | -0.2% | +1.4% | -0.4% | -4.1% | -0.5% | — |
| May 9, 2024 | AMC | 0.00 | -0.01 | -330.9% | 13.37 | -1.2% | -0.9% | -1.9% | +0.6% | +0.1% | -0.4% | — |
| Feb 1, 2024 | AMC | 0.10 | 0.51 | +420.5% | 14.38 | +0.2% | -0.7% | -3.2% | -1.5% | -1.4% | -2.6% | — |
| Oct 26, 2023 | AMC | 0.10 | 0.50 | +418.1% | 13.38 | +0.6% | +0.7% | -0.1% | +1.6% | +2.0% | +3.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 16 | TD Cowen | Maintains | Outperform → Outperform | — | $16.52 | $16.49 | -0.2% | -0.4% | -1.5% | -2.8% | -2.1% | -0.6% |
| Apr 4 | TD Cowen | Maintains | Outperform → Outperform | — | $16.52 | $16.50 | -0.1% | +0.9% | +0.1% | +3.3% | +0.6% | +0.1% |
| Mar 16 | BofA Securities | Upgrade | Neutral → Buy | — | $16.08 | $16.19 | +0.7% | +2.2% | +1.9% | +1.8% | +2.0% | +2.2% |
| Jul 19 | Cowen & Co. | Upgrade | Market Perform → Outperform | — | $14.41 | $14.74 | +2.3% | +1.7% | +0.5% | +2.1% | +1.4% | +1.5% |
| Oct 7 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $14.31 | $14.43 | +0.8% | +0.4% | -0.4% | -0.6% | -1.5% | -1.0% |
| Mar 11 | JP Morgan | Maintains | Overweight → Overweight | — | $17.90 | $17.47 | -2.4% | -4.2% | -15.7% | -16.6% | -25.1% | -21.7% |
| Nov 1 | Cowen & Co. | Maintains | Market Perform → Perform | — | $17.97 | $18.39 | +2.3% | +3.8% | +3.4% | +7.2% | +7.6% | +8.8% |
| Sep 24 | Jefferies | Maintains | Buy → Buy | — | $17.49 | $17.50 | +0.1% | +0.1% | +1.6% | +1.8% | -0.9% | -1.7% |
Data updated apr 27, 2026 3:55am
· Source: massive.com